| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥242.6B | ¥243.1B | -0.2% |
| Operating Income | ¥2.1B | ¥3.5B | -41.7% |
| Ordinary Income | ¥2.1B | ¥3.5B | -39.8% |
| Net Income | ¥2.9B | ¥0.3B | +709.5% |
| ROE | 1.5% | 0.2% | - |
Cumulative results for Q3 FY2026 recorded revenue of ¥242.6B (YoY -¥0.5B, -0.2%), remaining roughly flat, while operating income was ¥2.1B (YoY -¥1.4B, -41.7%) and ordinary income was ¥2.1B (YoY -¥1.4B, -39.8%), both declining significantly. Meanwhile, net income improved markedly to ¥2.9B (up ¥2.6B from ¥0.3B in the prior-year period). The operating margin fell to 0.9% (down 0.5pt from 1.4% in the prior-year period). The improvement in net income was supported by recording a ¥1.6B gain on sale of marketable securities, although a ¥2.6B valuation loss on investment securities also occurred. The full-year guidance remains for revenue of ¥335.0B (YoY +2.9%), operating income of ¥3.0B (YoY -49.5%), ordinary income of ¥1.0B (YoY -77.4%), and net income of ¥1.5B (YoY -66.5%), indicating an outlook for lower earnings.
[Profitability] ROE 1.5% (improved from 0.2% in the prior-year period, but relatively low versus the company’s 3-year average), operating margin 0.9% (down 0.5pt from 1.4% in the prior-year period), net margin 1.2% (up 1.1pt from 0.1% in the prior-year period), and an EBIT margin of 0.8% indicate extremely low profitability. [Cash Quality] Cash and deposits ¥34.3B; cash coverage of short-term liabilities is 1.88x, securing short-term liquidity. Interest coverage of 1.22x indicates vulnerability in debt service capacity. [Investment Efficiency] Total asset turnover 0.47x and ROIC 0.6% reflect low capital efficiency. Total assets increased to ¥521.0B, up ¥22.5B YoY. [Financial Soundness] Equity ratio 36.9% (down 1.6pt from 38.5% in the prior-year period), current ratio 228.0%, and quick ratio 176.9% indicate sound liquidity. Debt-to-equity ratio 1.71x, interest-bearing debt ¥133.4B, and Debt-to-Capital ratio 40.9%. Short-term borrowings were ¥3.9B, up ¥1.6B (+69.6%) from ¥2.3B in the prior-year period, indicating a shortening of the maturity profile.
Cash and deposits increased by ¥8.0B YoY to ¥34.3B, which is estimated to have been supported by higher operating profit and the sale of marketable securities as funding sources. In working capital, accounts receivable at ¥78.2B and inventories at ¥72.7B account for a large share of current assets, making inventory turnover and receivables collection key drivers of capital efficiency. Cash coverage of short-term liabilities is 1.88x, ensuring sufficient short-term payment capacity. Meanwhile, short-term borrowings surged by +69.6% YoY, requiring attention to changes in maturity structure and refinancing risk. With interest expense of ¥1.7B and operating income of ¥2.1B, interest coverage is limited to 1.22x, indicating that interest burden is structurally squeezing earnings. Regarding the funding source for dividend payments, while the cash balance and net income level suggest short-term capacity, the sustainability of coverage is difficult to assess because details of operating cash flow (OCF) are undisclosed.
With ordinary income at ¥2.1B and operating income at ¥2.1B, non-operating gains and losses are roughly balanced. Non-operating income of ¥2.0B mainly comprises dividend income received and interest income, while non-operating expenses of ¥2.0B are largely interest expense of ¥1.7B. In extraordinary items, a ¥1.6B gain on sale of marketable securities was recorded, while a ¥2.6B valuation loss on investment securities occurred, resulting in net extraordinary losses. Net income of ¥2.9B exceeded operating income due to the contribution of extraordinary gains, but earnings power generated from operating income remains fragile. Non-operating income accounts for 0.8% of revenue, and extraordinary gains account for 0.6%, indicating that non-recurring factors have a certain impact on the profit mix. While the details of OCF are undisclosed and the cash backing of earnings cannot be directly confirmed, the increase in cash balance indicates a certain cash generation capability.
[Position within Industry] (Reference information, in-house research) Compared with the pharmaceuticals industry (N=6 companies) as of Q3 2025, the following characteristics are observed. Profitability: The operating margin of 0.9% is well above the industry median of -189.5%, maintaining profitability, but this represents relative outperformance within an industry experiencing significant losses overall. The net margin of 1.2% also exceeds the industry median of -191.3%. Soundness: The equity ratio of 36.9% is well below the industry median of 68.2%, indicating relatively low capital accumulation within the industry. Liquidity: The current ratio of 228.0% is below the industry median of 610.0%, indicating a relatively thin liquidity buffer within the industry. Efficiency: ROE of 1.5% significantly exceeds the industry median of -48.8%, showing an advantage in terms of capital efficiency by maintaining profitability. The revenue growth rate of -0.2% is above the industry median of -10.8%, indicating maintenance of sales scale within the industry. While the pharmaceuticals industry as a whole includes many loss-making companies due to R&D investments, the company remains profitable; however, the absolute levels of profitability and capital efficiency are low, and its relative advantage within the industry is limited (Industry: Pharmaceuticals (6 companies), Comparison: Q3 2025, Source: In-house aggregation).
There are two key takeaways from the results. First, the operating margin remains extremely low at 0.9%, and the full-year outlook also projects operating income of ¥3.0B (YoY -49.5%), indicating lower earnings. Elevated SG&A levels and a lack of operating leverage persist as structural issues for profitability; absent improved SG&A efficiency and a higher mix of high value-added products, margin improvement will be difficult. Second, with interest coverage at 1.22x indicating weak debt service capacity, short-term borrowings increased by +69.6% YoY, shortening the maturity profile. The simultaneous presence of low operating income levels and heavy interest burden reduces resilience to changes in OCF and funding conditions, making improvements in operating efficiency and a review of the financial structure pressing issues.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. The industry benchmark is reference information aggregated by our company based on publicly available earnings data. Investment decisions are your own responsibility; please consult a professional as necessary before making any investment decisions.